Belgium· BE-AMP-SAM662595-00
Ryzodeg 100 U/ml
A insulin degludec und insulin aspart product containing insulin aspart, registered in Belgium by Novo Nordisk. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Insulin degludec und insulin aspart is registered in 9 of 19 countries.
Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Insulin degludec und insulin aspart · ATC A10AD06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Insulin Aspart
- Manufacturer
- Novo Nordisk
- Country
- Belgium (BE)
- ATC code
- A10AD06
- ATC class
- Insulin degludec und Insulin aspart
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec und insulin aspart in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- United States.Insulin Aspart Protamine and Insulin AspartA-S Medication Solutions
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- IrelandDazparda 100 units/ml solution for injection in pre-filled penGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9836ddb-0d43-4bed-be7d-34a5a5ffaecd GET /v1/drugs/e9836ddb-0d43-4bed-be7d-34a5a5ffaecd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ryzodeg 100 U/ml",
"name_fr": "Ryzodeg 100 U/ml",
"name_nl": "Ryzodeg 100 U/ml",
"amp_code": "SAM662595-00",
"strengths": [
"30.0000",
"30.0000",
"70.0000",
"70.0000"
],
"pack_count": 1,
"substances": [
"Insulin Aspart",
"Insulin Degludec",
"Glycerol",
"Sodium Chloride",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Insulin Degludec and Insulin Aspart",
"authorisation_numbers": [
"EU/1/12/806/009"
]
}See everything about insulin degludec und insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.